会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Quinazolines and phthalazines having adenosine uptake inhibitor activity
    • 喹唑啉和具有腺苷摄取抑制剂活性的酞嗪酮
    • US5648353A
    • 1997-07-15
    • US446235
    • 1995-05-22
    • Shigeki FujiwaraDaisuke MachiiHaruki TakaiHiromi NonakaHiroshi KaseKozo YaoMichiyo KawakageHideaki KusakaAkira Karasawa
    • Shigeki FujiwaraDaisuke MachiiHaruki TakaiHiromi NonakaHiroshi KaseKozo YaoMichiyo KawakageHideaki KusakaAkira Karasawa
    • C07D401/14C07D491/04C07D401/04A61K31/445A61K31/50A61K31/505
    • C07D401/14C07D491/04
    • The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C--R.sup.11 (wherein R.sup.11 represents hydrogen, substituted or unsubstituted lower alkyl, or halogen),or a pharmaceutically acceptable salt thereof as an active ingredient.
    • 本发明涉及腺苷摄取抑制剂和用于心肌保护或预防或治疗炎性水肿的药剂,其包含由式(I)表示的1,2,3,4-四氢-2,4-二氧代喹唑啉衍生物: (I)其中R 1表示氢,取代或未取代的低级烷基,烯基或取代或未取代的芳烷基; R2,R3,R4和R5独立地表示氢,卤素,氨基,一或二(低级烷基)氨基,低级烷酰基氨基,硝基,氰基,取代或未取代的低级烷基,羟基,低级烷氧基,低级烷硫基,羧基,低级 烷氧基羰基,低级烷酰基,芳烷氧基或低级烷酰氧基; R 6,R 7,R 8和R 9独立地表示氢,羟基,取代或未取代的低级烷氧基或芳烷氧基,或者它们中的任何相邻的两个被结合形成亚甲二氧基; R 10表示氢或低级烷基; 并且Y和Z独立地表示作为活性成分的N或C-R11(其中R11表示氢,取代或未取代的低级烷基或卤素)或其药学上可接受的盐。
    • 4. 发明授权
    • Benzotriazines having adenosine uptake inhibitor activity
    • 具有腺苷摄取抑制剂活性的苯并三嗪
    • US5605900A
    • 1997-02-25
    • US430227
    • 1995-04-28
    • Shigeki FujiwaraDaisuke MachiiHaruki TakaiHiromi NonakaHiroshi KaseKozo YaoMichiyo KawakageHideaki KusakaAkira Karasawa
    • Shigeki FujiwaraDaisuke MachiiHaruki TakaiHiromi NonakaHiroshi KaseKozo YaoMichiyo KawakageHideaki KusakaAkira Karasawa
    • C07D401/14C07D491/04C07D401/04A61K31/445A61K31/50A61K31/53
    • C07D401/14C07D491/04
    • The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C-R.sup.11 (wherein R.sup.11 represents hydrogen, substituted or unsubstituted lower alkyl, or halogen),or a pharmaceutically acceptable salt thereof as an active ingredient.
    • 本发明涉及腺苷摄取抑制剂和用于心肌保护或预防或治疗炎性水肿的药剂,其包含由式(I)表示的1,2,3,4-四氢-2,4-二氧代喹唑啉衍生物: (I)其中R 1表示氢,取代或未取代的低级烷基,烯基或取代或未取代的芳烷基; R2,R3,R4和R5独立地表示氢,卤素,氨基,一或二(低级烷基)氨基,低级烷酰基氨基,硝基,氰基,取代或未取代的低级烷基,羟基,低级烷氧基,低级烷硫基,羧基,低级 烷氧基羰基,低级烷酰基,芳烷氧基或低级烷酰氧基; R 6,R 7,R 8和R 9独立地表示氢,羟基,取代或未取代的低级烷氧基或芳烷氧基,或者它们中的任何相邻的两个被结合形成亚甲二氧基; R 10表示氢或低级烷基; 并且Y和Z独立地表示作为活性成分的N或C-R11(其中R11表示氢,取代或未取代的低级烷基或卤素)或其药学上可接受的盐。
    • 7. 发明授权
    • Isoquinolines having adenosine uptake inhibitor activity
    • 具有腺苷摄取抑制剂活性的异喹啉
    • US5658917A
    • 1997-08-19
    • US430234
    • 1995-04-28
    • Shigeki FujiwaraDaisuke MachiiHaruki TakaiHiromi NonakaHiroshi KaseKozo YaoMichiyo KawakageHideaki KusakaAkira Karasawa
    • Shigeki FujiwaraDaisuke MachiiHaruki TakaiHiromi NonakaHiroshi KaseKozo YaoMichiyo KawakageHideaki KusakaAkira Karasawa
    • C07D401/14C07D491/04A61K31/445A61K31/50A61K31/505
    • C07D401/14C07D491/04
    • The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C--R.sup.11 (wherein R.sup.11 represents hydrogen, substituted or unsubstituted lower alkyl, or halogen),or a pharmaceutically acceptable salt thereof as an active ingredient.
    • 本发明涉及腺苷摄取抑制剂和用于心肌保护或预防或治疗炎性水肿的药剂,其包含由式(I)表示的1,2,3,4-四氢-2,4-二氧代喹唑啉衍生物: (I)其中R 1表示氢,取代或未取代的低级烷基,烯基或取代或未取代的芳烷基; R2,R3,R4和R5独立地表示氢,卤素,氨基,一或二(低级烷基)氨基,低级烷酰基氨基,硝基,氰基,取代或未取代的低级烷基,羟基,低级烷氧基,低级烷硫基,羧基,低级 烷氧基羰基,低级烷酰基,芳烷氧基或低级烷酰氧基; R 6,R 7,R 8和R 9独立地表示氢,羟基,取代或未取代的低级烷氧基或芳烷氧基,或者它们中的任何相邻的两个被结合形成亚甲二氧基; R 10表示氢或低级烷基; 并且Y和Z独立地表示作为活性成分的N或C-R11(其中R11表示氢,取代或未取代的低级烷基或卤素)或其药学上可接受的盐。
    • 9. 发明授权
    • Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors
    • 哌啶基 - 二氧喹唑啉作为腺苷再摄取抑制剂
    • US5624926A
    • 1997-04-29
    • US318876
    • 1994-10-17
    • Shigeki FujiwaraDaisuke MachiiHaruki TakaiHiromi NonakaHiroshi KaseKozo YaoMichiyo KawakageHideaki KusakaAkira Karasawa
    • Shigeki FujiwaraDaisuke MachiiHaruki TakaiHiromi NonakaHiroshi KaseKozo YaoMichiyo KawakageHideaki KusakaAkira Karasawa
    • C07D401/14C07D491/04A61K31/50A61K31/505
    • C07D401/14C07D491/04
    • The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C--R.sup.11 (wherein R.sup.11 represents hydrogen, substituted or unsubstituted lower alkyl, or halogen),or a pharmaceutically acceptable salt thereof as an active ingredient.
    • PCT No.PCT / JP94 / 00229 Sec。 371日期:1994年10月17日 102(e)日期1994年10月17日PCT 1994年2月16日PCT PCT。 WO94 / 19342 PCT公开号 日期:1994年9月1日本发明涉及一种腺苷摄取抑制剂和用于心肌保护或预防或治疗炎性水肿的药剂,其包含1,2,3,4-四氢-2,4-二氧代喹唑啉衍生物 式(I):其中R 1表示氢,取代或未取代的低级烷基,烯基或取代或未取代的芳烷基; R2,R3,R4和R5独立地表示氢,卤素,氨基,一或二(低级烷基)氨基,低级烷酰基氨基,硝基,氰基,取代或未取代的低级烷基,羟基,低级烷氧基,低级烷硫基,羧基,低级 烷氧基羰基,低级烷酰基,芳烷氧基或低级烷酰氧基; R 6,R 7,R 8和R 9独立地表示氢,羟基,取代或未取代的低级烷氧基或芳烷氧基,或者它们中的任何相邻的两个被结合形成亚甲二氧基; R 10表示氢或低级烷基; 并且Y和Z独立地表示作为活性成分的N或C-R11(其中R11表示氢,取代或未取代的低级烷基或卤素)或其药学上可接受的盐。